The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV
activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a
daily basis for 2 weeks to HIV-infected patients.